Double‐blind comparison of 5‐aminosalicylic acid and acetyl‐5‐aminosalicylic acid suppositories in patients with idiopathic proctitis
- 1 February 1988
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 2 (1) , 33-40
- https://doi.org/10.1111/j.1365-2036.1988.tb00668.x
Abstract
Suppositories containing 300 mg 5‐aminosalicylic acid (1.96 mmol) or 425 mg acety1‐5‐aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl‐5‐aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5‐aminosalicylic acid or acetyl‐5‐aminosalicylic acid suppositories twice daily for 4 weeks in a double‐blind trial. Four patients were included twice in the trial. The second time they were treated with the alternative regimen. Six patients in the acetyl‐5‐aminoscylic acid group did not complete the trial, four of them because of diarrhoea. Complete clinical remission with normal rectal mucosa on sigmoidoscopy was achieved in 10 out of 18 patients on 5‐aminosalicylic acid and in only two out of 15 in the acetyl‐5‐aminosalicylic acid group (P= 0.03). A favourable histological improvement was demonstrated with 5‐aminosalicylic acid suppositories, but the difference with acetyl‐5‐aminosalicylic acid was not significant (P= 0.059). Three of the four patients who received both drugs recovered with 5‐aminosalicylic acid; in none of them was acetyl‐5‐aminosalicylic acid effective. The results from this study and from previous investigations show that acetyl‐5‐aminosalicylic acid is not superior to placebo.Keywords
This publication has 19 references indexed in Scilit:
- Disposition of disodium azodisalicylate in healthy subjectsGastroenterology, 1985
- Determination of sodium azodisalicylate, salazosulphapyridine and their metabolites in serum, urine and faeces by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- 5-AMINOSALICYLIC ACID AS RECTAL ENEMA IN ULCERATIVE COLITIS PATIENTS UNABLE TO TAKE SULPHASALAZINEThe Lancet, 1984
- Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.Gut, 1982
- TREATMENT OF ULCERATIVE COLITIS WITH HIGH-DOSE 5-AMINOSALICYLIC ACID ENEMASThe Lancet, 1981
- Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.Gut, 1980
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977
- Adverse Reactions during Salicylazosulfapyridine Therapy and the Relation with Drug Metabolism and Acetylator PhenotypeNew England Journal of Medicine, 1973
- Absorption, metabolism, and excretion of salicylazosulfapyridine in manClinical Pharmacology & Therapeutics, 1972
- Variation Between Observers in Describing Mucosal Appearances in ProctocolitisBMJ, 1964